|
|
| Find this article at: http://www.UtilityComputing.com/news/358.asp |
|
Drug Discovery Technology the target for United Devices and Optive Research [UC Newsdesk 2003/8/4]
United Devices has announced a partnership with life sciences software company, Optive Research to develop software for computer-assisted drug discovery (CADD) specifically optimized for United Devices' grid computing platform. The partnership should allow pharmaceutical companies to speed lead identification and lead optimization phases of the drug discovery process resulting in the development of novel cheminformatic and molecular design software that was previously impossible or impractical. "The most obvious benefit of supporting the United Devices Grid MP platform will be to give our customers the ability to obtain CADD results much faster than by simply using individual high-end servers or clusters," said Bryan Koontz, vice president of marketing at Optive Research. "More importantly, however, grid computing will enable Optive to develop software that gives life science researchers the ability to do things differently and more completely, reducing the traditional compromise between speed and scientific rigor." Optive Research, which recently announced the corporation's launch, was created by respected scientist Professor Robert S. Pearlman to help researchers bring beneficial chemical compounds, primarily new drugs and agrochemicals, to market faster and at a lower cost. "Many pharmaceutical companies are starting to realize that grid computing can be an important source of competitive advantage in drug research and development," said United Devices' Director of Global Grid Services, Piush Patel. "Grid-enabling key discovery applications such as those in Optive's software portfolio is an important first step in increasing the speed and scope of molecular research." |
|
|